Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at RBC Capital. 2. Visteon (VC) initiated with a Sector Perform at RBC Capital. 3. Allscripts (MDRX) initiated with a Neutral at BofA/Merrill. 4. Independent Bank (INDB) initiated with a Neutral at Piper Jaffray. 5. Karyopharm (KPTI) initiated with an Overweight at Cantor. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

Sees 2024 adjusted EBITDA $470M-$500M and adjusted free cash flow $155M-$185M.

Reports Q1 revenue $933M, consensus $977.87M. "Our first quarter results highlight our continued progress on addressing the megatrends of digitalization and electrification that are rapidly changing the automotive industry. I am very proud of our continued operational execution and launching a high number of new products across the globe to support our customers and deliver near-term growth," said CEO Sachin Lawande. "We are also strengthening our future with another strong quarter of new business wins across our digital cockpit products while further diversifying into adjacent end markets."